title: [Aspergillosis in cystic fibrosis patients].
abstract: Allergic bronchopulmonary aspergillosis (ABPA) should be suspected in any CF patient whose pulmonary disease deteriorates precipitously, suddenly or unexpectedly, and has to be correlated to fungal hypersensitivity biological tests. The standard therapeutic approach is based upon systemic corticosteroids. Invasive pulmonary aspergillosis (IPA) may occur mainly but not exclusively in immunosuppressed patients undergoing lung transplantation. New antifungal compounds (Triazoles, Itraconazole, Voriconazole), Echinochandins (Caspofungin) are effective, synergistic, well tolerated, should their contraindications and side effects be carefully respected and monitored.
authors.affiliation: CRCM Lisieux, service de pédiatrie, CHG R. Bisson, 4, rue Aini, 14100 Lisieux, France. pedia@ch-lisieux.fr
authors.forename: M
authors.initials: M
authors.lastname: Guillot
authors.forename: C
authors.initials: C
authors.lastname: El Hachem
authors.forename: M
authors.initials: M
authors.lastname: Amiour
authors.forename: B
authors.initials: B
authors.lastname: Delaisi
authors.forename: P
authors.initials: P
authors.lastname: Reinert
mesh_terms: D001228:Aspergillosis / Q000150:complications* / Q000188:drug therapy; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000150:complications / Q000188:drug therapy; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000150:complications* / Q000188:drug therapy